Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Filamon LTD
AstraZeneca
UMC Utrecht
Eastern Cooperative Oncology Group
City of Hope Medical Center
Essen Biotech
Essen Biotech
Wake Forest University Health Sciences
Stemline Therapeutics, Inc.
Iambic Therapeutics, Inc
Barbara Ann Karmanos Cancer Institute
University of Nebraska
Adela, Inc
Orano Med LLC
NRG Oncology
NRG Oncology
Var2 Pharmaceuticals
Hoosier Cancer Research Network
Mayo Clinic
Sunnybrook Health Sciences Centre
University of Rochester
Mayo Clinic
University of Washington
City of Hope Medical Center
Beijing Biostar Pharmaceuticals Co., Ltd.
Mayo Clinic
Massive Bio, Inc.
Mayo Clinic
SWOG Cancer Research Network
Guangzhou Medical University
LigaChem Biosciences, Inc.
Institut Cancerologie de l'Ouest
Jonsson Comprehensive Cancer Center
Columbia University
Weill Medical College of Cornell University
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Algemeen Ziekenhuis Maria Middelares
The New York Proton Center
Dana-Farber Cancer Institute
University of Sydney
Peking Union Medical College Hospital
Second Affiliated Hospital of Guangzhou Medical University
Samsung Medical Center
Avera McKennan Hospital & University Health Center
A.O.U. Città della Salute e della Scienza
Hospices Civils de Lyon